Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01352520 · ClinicalTrials.gov registry record · Phase 2
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
A Phase 2 study of Lymphoma and Mycosis Fungoides, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT01352520: Active Phase 2 study of Lymphoma and Mycosis Fungoides, sponsored by M.D. Anderson Cancer Center.
NCT01352520 is a Phase 2 study of Lymphoma and Mycosis Fungoides that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 79 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01352520, a Phase 2 study of Lymphoma and Mycosis Fungoides, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.
Primary Outcome
Response rate is percentage of participants with skin lesions that express CD30+ receiving SGN-35 in primary cutaneous ALCL, MF, and extensive lymphomatoid papulosis whose best response during the observation period is a Partial Response (PR), regression of measurable disease, or Complete Response (CR), complete disappearance of all clinical evidence of disease, (i.e. at least moderate improvement). Objective tumor response (PR, CR, PR+CR) based on Response Evaluation Criteria In Solid Tumors (R
Conditions Studied
Interventions
- DRUG SGN-35
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2011-06 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 2 |
What the registry record for NCT01352520 still lists
NCT01352520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 79 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (84% lower).
The record links to 8 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which SGN-35 is the first listed.
NCT01352520 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01352520 about?
NCT01352520 is a clinical study titled "SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)". The goal of this clinical research study is to learn if SGN-35 (brentuximab vedotin) can help to control ALCL, LyP or MF in patients with at least 1 of the 3 skin lymphomas. The safety of the study drug will also be studied.
What is the current status of trial NCT01352520?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2011-06. Estimated completion is 2028-01-31.
What conditions does trial NCT01352520 study?
This clinical trial studies the following conditions: Lymphoma, Mycosis Fungoides, Lymphomatoid Papulosis, Hematologic Disorder, CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma.
What interventions are being tested in trial NCT01352520?
The interventions under investigation include: SGN-35 (DRUG).
Who is sponsoring clinical trial NCT01352520?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01352520 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01352520's enrollment target sits among peer trials
79 105th of 299 higher than 195 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05798897 · 79 participants · Phase 1
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- NCT06042439 · 79 participants · NA
AM vs PM Exercise Training
- NCT06223555 · 79 participants · NA
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia